Fuller & Thaler Asset Management Inc. Trims Stake in Bruker Corporation $BRKR

Key Points

• Fuller & Thaler Asset Management Inc. significantly reduced its stake in Bruker Corporation by 99.6% in the first quarter, owning only 1,309 shares after selling 333,225 shares.
• Bruker Corporation reported $0.32 EPS for the last quarter, which was below analysts' expectations of $0.33, and had a net revenue of $797.40 million, down 0.4% year-over-year.
• The company announced a quarterly dividend of $0.05 per share, with the next payment scheduled for October 3rd, representing a 0.6% dividend yield.

Fuller & Thaler Asset Management Inc. trimmed its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 99.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,309 shares of the medical research company's stock after selling 333,225 shares during the quarter. Fuller & Thaler Asset Management Inc.'s holdings in Bruker were worth $55,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of BRKR. London Co. of Virginia grew its stake in shares of Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock worth $245,820,000 after purchasing an additional 1,843,294 shares during the last quarter. Sculptor Capital LP grew its stake in Bruker by 484.1% in the 4th quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock worth $100,476,000 after acquiring an additional 1,420,569 shares in the last quarter. Steadfast Capital Management LP bought a new position in shares of Bruker during the fourth quarter valued at approximately $63,997,000. Nuveen LLC purchased a new position in shares of Bruker in the first quarter worth $20,764,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Bruker during the first quarter valued at $19,369,000. 79.52% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Bruker news, CEO Frank H. Laukien acquired 2,608 shares of the stock in a transaction on Friday, June 6th. The shares were purchased at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the acquisition, the chief executive officer owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. This represents a 0.01% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 27.30% of the stock is owned by insiders.

Analyst Ratings Changes

BRKR has been the topic of several recent analyst reports. Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the stock a "buy" rating in a report on Monday, August 4th. Stifel Nicolaus set a $40.00 price target on shares of Bruker and gave the company a "hold" rating in a report on Tuesday, August 5th. The Goldman Sachs Group reduced their target price on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Barclays decreased their price objective on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Monday, August 4th. Finally, Bank of America decreased their target price on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Five research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, Bruker presently has a consensus rating of "Hold" and an average price target of $51.30.

Bruker Trading Down 1.3%

BRKR traded down $0.44 during trading hours on Wednesday, reaching $33.63. The company's stock had a trading volume of 664,293 shares, compared to its average volume of 2,440,190. The stock has a market cap of $5.10 billion, a PE ratio of 64.49, a P/E/G ratio of 2.86 and a beta of 1.16. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. Bruker Corporation has a fifty-two week low of $30.00 and a fifty-two week high of $72.94. The business's 50-day moving average is $38.32 and its 200-day moving average is $40.63.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $797.40 million during the quarter, compared to analysts' expectations of $811.17 million. During the same period in the previous year, the company posted $0.52 EPS. Bruker's quarterly revenue was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. As a group, equities research analysts predict that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be paid a $0.05 dividend. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker's payout ratio is 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.